Evidence map›Paper›PMID 28959457›Full record

ArticleActa radiologica open2017

Hemangioma of the rib showing a relatively high 18F-FDG uptake: a case report with a literature review.

Takahide Itabashi, Makoto Emori, Yoshinori Terashima, Tadashi Hasegawa, Junya Shimizu, Satoshi Nagoya, Toshihiko Yamashita

Open access · goldAbstract readCase Reports
In one paragraph

Article in Acta radiologica open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Radiology case reports · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020
    Review
  10. Article
  11. False-positive FDG PET CT Scan in Vertebral Hemangioma.Asia Oceania journal of nuclear medicine & biology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Takahide ItabashiSapporo Medical University School of Medicine, Sapporo, Japan.
Makoto EmoriSapporo Medical University School of Medicine, Sapporo, Japan.
Yoshinori TerashimaSapporo Medical University School of Medicine, Sapporo, Japan.
Tadashi HasegawaSapporo Medical University School of Medicine, Sapporo, Japan.
Junya ShimizuSapporo Medical University School of Medicine, Sapporo, Japan.
Satoshi NagoyaSapporo Medical University School of Medicine, Sapporo, Japan.
Toshihiko YamashitaSapporo Medical University School of Medicine, Sapporo, Japan.
Sapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemangioma of the rib is a rare benign tumor that is often difficult to distinguish from malignant bone tumors. Rib hemangioma often shows bony disruption with a slight cortical disruption, extraosseous lesion, and expanded bone on computed tomography (CT). We report the case of a 68-year-old man with atypical rib hemangioma with a slight cortical disruption and no expanded bone. The tumor showed relatively high 18FDG-uptake on positron emission tomography (PET)/CT. Rib hemangioma often shows higher 18FDG-uptake. PET/CT may not provide useful information for distinguishing rib hemangioma from a malignant tumor. Close observation without surgical resection may be feasible if the tumor is diagnosed as a rib hemangioma by biopsy.

Indexed as

18F-fluorodeoxyglucose (FDG)computed tomography (CT)hemangiomapositron emission tomography (PET)rib

Identifiers

PMID28959457
PMCPMC5593230
OpenAlexW2752021647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.